Northwest Biotherapeutics (NWBO) – Press Releases
-
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
-
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
-
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
-
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
-
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
-
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
-
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
-
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
-
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
-
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
-
Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation
-
Cohen Milstein reicht im Namen von Northwest Biotherapeutics Klage gegen die wichtigsten Market Maker wegen Marktmanipulation ein
-
Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation
-
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
-
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
-
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
-
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
-
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
-
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
-
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
-
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility
-
Northwest Biotherapeutics Announces $15 Million Financing
-
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
-
UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)
-
UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)
-
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
-
Northwest Biotherapeutics Announces Data Lock of Phase III Trial
-
Northwest Biotherapeutics Acquires Flaskworks
-
NW Bio Accelerating Sawston Plant Phase I Buildout
-
Northwest Biotherapeutics Announces $5 Million Financing
-
NW Bio Announces Completion of Further Data Gathering For Phase III Trial
-
Northwest Biotherapeutics Announces $8 Million Financing
-
Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases
-
NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
-
NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
-
NW Bio Announces Annual Shareholders' Meeting Scheduled for April 18, 2020
-
Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team
-
Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit
-
NW Bio Moves Forward With SEC Settlement
-
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
-
Highlights Of NW Bio's Program Update In The Industry Expert Theater Presentation At ASCO
-
NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO
-
NW Bio Announces Settlement with Cognate BioServices Resolving Past Matters and Providing for Restart of DCVax®-Direct Production
-
NW Bio Hires David Innes As Vice President, Investor Relations
-
NW Bio Releases Voting Results From Annual Shareholders' Meeting
-
Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference
-
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds
-
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction
-
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference
-
NW Bio Announces $5 Million Bridge Funding
Back to NWBO Stock Lookup
